ArticleNephrology (Carlton, Vic.)2021
Safety and utility of kidney biopsy in patients with estimated glomerular filtration rate < 30 ml/min/1.73 m
Article in Nephrology (Carlton, Vic.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
- Lower eGFR is independently associated with embolization‑requiring severe bleeding after percutaneous renal biopsy: a matched case-control study with dose-respons e analysis.Renal failure · 2026Article
- Reporting of Perirenal Hematoma Size After Ultrasound-Guided Renal Biopsy in Adults: A Scoping Review.Biomedicines · 2025Review
- Essential role of kidney biopsy in diagnosing glomerular diseases amidst evolving biomarkers.World journal of nephrology · 2025Article
- Image-guided renal parenchymal biopsies- how we do it.Abdominal radiology (New York) · 2025Review
- The safety of percutaneous renal biopsy for acute kidney injury in metastatic renal cell cancer patients with reduced nephron mass.Frontiers in nephrology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 3 countries.
Funding
Abstract
aimKidney biopsy (KBx) is the gold standard for evaluation of kidney disease, but is associated with a higher risk of complications in patients with reduced glomerular filtration rate (GFR). We studied the safety and utility of KBx in patients with eGFR <30 ml/min/1.73 m
methodsConsecutive adult patients with eGFR <30 ml/min/1.73 m
resultsOf the 126 patients included, 75% were male, 27.7% were diabetic, and the median eGFR was 13.5 ml/min/1.73m
conclusionKBx is relatively safe in severe kidney disease but its risk to benefit balance needs to be carefully considered when eGFR is <15 ml/min/1.73m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.